Hemorheological background of acetylsalicylic acid resistance.

G. Fehér, Katalin Koltai, Gabor Kesmarky, K. Tóth

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND: Pathologic hemorheological parameters and increased platelet aggregation in association with other risk factors significantly increase the possibility of the development of ischemia. Acetylsalicylic acid (ASA) is an effective antithrombotic agent, which prevents a variety of cardiovascular diseases. OBJECTIVES: The aim of our present study was to compare the hemorheological parameters of patients with effective platelet inhibition by ASA to those with ineffective one. METHODS: 2045 patients taking 100 mg ASA daily were involved in our study (1255 males, mean age: 63+/-11 yrs, 790 females, mean age: 63+/-12 yrs). To exclude the effect of risk profile, previous diseases and medication, 323 patients (197 males, mean age 60+/-13 yrs and 126 females, mean age 60+/-12 yrs) were selected from the examined group with matching parameters. Blood was taken after an overnight fast between 8:00 and 9:00 a.m. Platelet aggregation was measured in Carat TX-4 optical platelet aggregometer. Blood hematocrit was measured by Heraeus microhematocrit centrifuge and red blood cell aggregation was detected by Myrenne aggregometer. Plasma fibrinogen was measured by Clauss' method. Plasma and whole blood viscosities were measured in Hevimet 40 capillary viscosimeter. RESULTS: Patients with effective ASA inhibition had significantly lower plasma fibrinogen level (p

Original languageEnglish
Pages (from-to)143-152
Number of pages10
JournalClinical Hemorheology and Microcirculation
Volume38
Issue number3
Publication statusPublished - 2008

Fingerprint

Aspirin
Platelet Aggregation
Fibrinogen
Blood Platelets
Cell Aggregation
Blood Viscosity
Fibrinolytic Agents
Hematocrit
Cardiovascular Diseases
Ischemia
Erythrocytes

ASJC Scopus subject areas

  • Hematology
  • Physiology

Cite this

Hemorheological background of acetylsalicylic acid resistance. / Fehér, G.; Koltai, Katalin; Kesmarky, Gabor; Tóth, K.

In: Clinical Hemorheology and Microcirculation, Vol. 38, No. 3, 2008, p. 143-152.

Research output: Contribution to journalArticle

@article{07197c25076d45f38bd39125dcc1e57b,
title = "Hemorheological background of acetylsalicylic acid resistance.",
abstract = "BACKGROUND: Pathologic hemorheological parameters and increased platelet aggregation in association with other risk factors significantly increase the possibility of the development of ischemia. Acetylsalicylic acid (ASA) is an effective antithrombotic agent, which prevents a variety of cardiovascular diseases. OBJECTIVES: The aim of our present study was to compare the hemorheological parameters of patients with effective platelet inhibition by ASA to those with ineffective one. METHODS: 2045 patients taking 100 mg ASA daily were involved in our study (1255 males, mean age: 63+/-11 yrs, 790 females, mean age: 63+/-12 yrs). To exclude the effect of risk profile, previous diseases and medication, 323 patients (197 males, mean age 60+/-13 yrs and 126 females, mean age 60+/-12 yrs) were selected from the examined group with matching parameters. Blood was taken after an overnight fast between 8:00 and 9:00 a.m. Platelet aggregation was measured in Carat TX-4 optical platelet aggregometer. Blood hematocrit was measured by Heraeus microhematocrit centrifuge and red blood cell aggregation was detected by Myrenne aggregometer. Plasma fibrinogen was measured by Clauss' method. Plasma and whole blood viscosities were measured in Hevimet 40 capillary viscosimeter. RESULTS: Patients with effective ASA inhibition had significantly lower plasma fibrinogen level (p",
author = "G. Feh{\'e}r and Katalin Koltai and Gabor Kesmarky and K. T{\'o}th",
year = "2008",
language = "English",
volume = "38",
pages = "143--152",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Hemorheological background of acetylsalicylic acid resistance.

AU - Fehér, G.

AU - Koltai, Katalin

AU - Kesmarky, Gabor

AU - Tóth, K.

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Pathologic hemorheological parameters and increased platelet aggregation in association with other risk factors significantly increase the possibility of the development of ischemia. Acetylsalicylic acid (ASA) is an effective antithrombotic agent, which prevents a variety of cardiovascular diseases. OBJECTIVES: The aim of our present study was to compare the hemorheological parameters of patients with effective platelet inhibition by ASA to those with ineffective one. METHODS: 2045 patients taking 100 mg ASA daily were involved in our study (1255 males, mean age: 63+/-11 yrs, 790 females, mean age: 63+/-12 yrs). To exclude the effect of risk profile, previous diseases and medication, 323 patients (197 males, mean age 60+/-13 yrs and 126 females, mean age 60+/-12 yrs) were selected from the examined group with matching parameters. Blood was taken after an overnight fast between 8:00 and 9:00 a.m. Platelet aggregation was measured in Carat TX-4 optical platelet aggregometer. Blood hematocrit was measured by Heraeus microhematocrit centrifuge and red blood cell aggregation was detected by Myrenne aggregometer. Plasma fibrinogen was measured by Clauss' method. Plasma and whole blood viscosities were measured in Hevimet 40 capillary viscosimeter. RESULTS: Patients with effective ASA inhibition had significantly lower plasma fibrinogen level (p

AB - BACKGROUND: Pathologic hemorheological parameters and increased platelet aggregation in association with other risk factors significantly increase the possibility of the development of ischemia. Acetylsalicylic acid (ASA) is an effective antithrombotic agent, which prevents a variety of cardiovascular diseases. OBJECTIVES: The aim of our present study was to compare the hemorheological parameters of patients with effective platelet inhibition by ASA to those with ineffective one. METHODS: 2045 patients taking 100 mg ASA daily were involved in our study (1255 males, mean age: 63+/-11 yrs, 790 females, mean age: 63+/-12 yrs). To exclude the effect of risk profile, previous diseases and medication, 323 patients (197 males, mean age 60+/-13 yrs and 126 females, mean age 60+/-12 yrs) were selected from the examined group with matching parameters. Blood was taken after an overnight fast between 8:00 and 9:00 a.m. Platelet aggregation was measured in Carat TX-4 optical platelet aggregometer. Blood hematocrit was measured by Heraeus microhematocrit centrifuge and red blood cell aggregation was detected by Myrenne aggregometer. Plasma fibrinogen was measured by Clauss' method. Plasma and whole blood viscosities were measured in Hevimet 40 capillary viscosimeter. RESULTS: Patients with effective ASA inhibition had significantly lower plasma fibrinogen level (p

UR - http://www.scopus.com/inward/record.url?scp=43649100470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43649100470&partnerID=8YFLogxK

M3 - Article

C2 - 18239256

AN - SCOPUS:43649100470

VL - 38

SP - 143

EP - 152

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 3

ER -